A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure
Elnawam, A., Ezzeddin, S., Mostafa, A. (2024). A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure. EKB Journal Management System, 6(6), 4580-4588. doi: 10.21608/ijma.2023.220620.1727
Ali Hamed Basyouni Elnawam; Shaker Mahmoud Ezzeddin; Amr Mohamed Mostafa. "A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure". EKB Journal Management System, 6, 6, 2024, 4580-4588. doi: 10.21608/ijma.2023.220620.1727
Elnawam, A., Ezzeddin, S., Mostafa, A. (2024). 'A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure', EKB Journal Management System, 6(6), pp. 4580-4588. doi: 10.21608/ijma.2023.220620.1727
Elnawam, A., Ezzeddin, S., Mostafa, A. A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure. EKB Journal Management System, 2024; 6(6): 4580-4588. doi: 10.21608/ijma.2023.220620.1727

A Double-Blinded Placebo Controlled Therapeutic Trial on Patients with Stable Non-Segmental Vitiligo Using A Specially Formulated Reducing Gel [Pseudo-Catalase] Enhanced by Narrow Band Ultraviolet B Exposure

International Journal of Medical Arts
Article 14, Volume 6, Issue 6, June 2024, Page 4580-4588  XML PDF (1.87 MB)
Document Type: Original Article
DOI: 10.21608/ijma.2023.220620.1727
View on SCiNiTO View on SCiNiTO
Authors
Ali Hamed Basyouni Elnawam email 1; Shaker Mahmoud Ezzeddin2; Amr Mohamed Mostafa2
1Department of Dermatology, Venereology and Andrology, Al-Hud Al-Marsoud Hospital, Cairo, Egypt
2Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Abstract
Background: Vitiligo is a skin disorder characterized by the loss of melanocyte cells, leading to depigmentation. Treatment options for Vitiligo encompass topical agents, systemic treatments, phototherapy, and surgical interventions. Some therapeutic approaches target the oxidative toxicity pathway, with pseudo-catalase enzyme treatment showing promise in this context.
Aim of the Study: This study aims to assess the effectiveness and safety of a specially formulated reducing gel containing pseudo-catalase enzyme in conjunction with narrowband UVB therapy for stable non-segmental vitiligo.
Patients and Methods: In this double-blinded, placebo-controlled trial, 30 vitiligo patients were enrolled and randomly assigned to either the test gel group or the placebo gel group. Participants applied the assigned gel pre- and post-NBUVB treatment twice weekly for 24 weeks. Baseline and monthly assessments of Vitiligo Area Scoring Index [VASI] and photographic evaluations were conducted.
Results: The VASI scores of the test group exhibited a significant improvement [P value=0.0001] compared to the placebo group [P value=0.18] following treatment. Furthermore, post-treatment VASI scores were significantly lower in the test group compared to the placebo group.
Conclusion: The combination of pseudo-catalase reducing gel with NB-UVB therapy yields superior therapeutic benefits for stable non-segmental vitiligo in terms of repigmentation compared to NB-UVB therapy or placebo alone. These agents may enhance endogenous catalase activity through exogenous redox regulation, suggesting the need for further investigation.
Keywords
Vitiligo; Ultraviolet Therapy; Pigmentation Disorders
Statistics
Article View: 225
PDF Download: 112